We evaluated the predictability of self-reported Health-related quality of life (HRQoL) assessed by the 3-level 5-dimensional Euro-Quality of Life tool (EQ-5D-3L) and the EQ-Visual Analog Scale (EQ-VAS) on clinical outcomes of elderly patients who were admitted to an acute geriatric ward. A total of 102 participants (56.9% men) with a median age of 81.0 years (interquartile range or IQR: 76.0–85.3 years) were studied. The age-adjusted Charlson comorbidity index was 5.0 (IQR: 4.0–6.0) with a median length of stay (LOS) of 9.0 days (IQR: 7.0–15.0 days). No death occurred during hospitalization, and within 30 days after discharge, 15 patients were readmitted. During hospitalization, the EQ-5D-3L index was 0.440 at admission and that improved to 0.648 at discharge (p < 0.001). EQ-VAS scores also improved similarly from 60 to 70 (p < 0.001). Physical, cognitive function, frailty parameters (hand grip strength and walking speed), and nutritional status at admission all improved significantly during hospitalization and were related to EQ-5D-3L index or EQ-VAS scores at discharge. After controlling for relevant factors, EQ-5D-3L index at admission was found to be associated with LOS. In addition, EQ-VAS was marginally related to readmission. HRQoL assessment during hospitalization could be useful to guide clinical practice and to improve outcome.

Cognitive dysfunction commonly occurs among older patients during admission and is associated with adverse prognosis. This study evaluated clinical characteristics and outcome determinants in hospitalized older patients with cognitive disorders. The main outcomes were length of stay, readmission within 30 days, Barthel index (BI) score at discharge, BI score change (discharge BI score minus BI score), and proportion of positive BI score change to indicate change of activities of daily living (ADL) change during hospitalization. A total of 642 inpatients with a mean age of 79.47 years (76–103 years) were categorized into three groups according to the medical history of dementia, and Mini-Mental State Examination (MMSE) scores at admission. Among them, 74 had dementia diagnosis (DD), 310 had cognitive impairment (CI), and 258 had normal MMSE scores. Patients with DD and CI generally had a higher risk of many geriatric syndromes, such as multimorbidities, polypharmacy, delirium, incontinence, visual and auditory impairment, fall history, physical frailty. They had less BI score, BI score change, and proportion of positive BI score change ADL at discharge. (DD 70.0%, CI 79.0%), suggesting less ADL change during hospitalization compared with those with normal MMSE scores (92.9%; p < 0.001). Using multiple regression analysis, we found that among patients with DD and CI, age (p = 0.008) and walking speed (p = 0.023) were predictors of discharge BI score. In addition, age (p = 0.047) and education level were associated with dichotomized BI score change (positive vs. non-positive) during hospitalization. Furthermore, the number and severity of comorbidities predicted LOS (p < 0.001) and readmission (p = 0.001) in patients with cognitive disorders. It is suggested that appropriate strategies are required to improve clinical outcomes in these patients.

Purpose: Sarcopenia (SP) and osteoporosis (OP) both pose higher risks for adverse health outcomes. This study explored the relationship among sarcopenia, osteoporosis and all-cause mortality. Patients and Methods: This retrospective cohort utilized a tertiary-hospital-based cohort during the years from 2018 to 2024. Patients received dual-energy X-ray absorptiometry scans. Osteoporosis was diagnosed when T-scores of <-2.5 were determined at the L-spine or femoral neck. Sarcopenia was defined using the Asian Working Group for Sarcopenia 2019 criteria: low muscle strength, low physical performance, and a low appendicular skeletal mass index. We utilized the Cox proportional hazard model and Kaplan-Meier curves to depict observed time to mortality. Post-hoc analysis was applied for subgroup comparison and statistical power calculation. Interaction terms sensitivity analysis was used for analyzing mutually exclusive groups. Results: A total of 545 patients (median age [interquartile range] 68.7 [52.8– 80.7] years; 72.3% women) were analyzed. At baseline, 15.6% had SP alone, 23.1% had OP alone, and 14.3% had both conditions. Over median 0.7 (interquartile range = 0.2– 1.4) years of follow-up, 24 deaths occurred. Older age, multimorbidity, sarcopenia, and osteoporosis were significantly associated with higher mortality. In multivariable analysis adjusting for age and multimorbidity, sarcopenia alone was a stronger predictor of mortality compared to osteoporosis alone (hazard ratio [HR] 7.34 vs 3.99), and the mortality HR was 7.34 for sarcopenia with or without osteoporosis higher than 3.99 for osteoporosis with/without sarcopenia. Interaction analysis was not feasible in the four-group comparison, as the interaction term overlapped with the ‘both sarcopenia and osteoporosis’ group; in the other three groups, the SP×OP interaction was not significant. SP patients were more likely to be older, male, and have lower body mass index, total tissue, and lean mass. Conclusion: These findings suggest that sarcopenia may be a more important predictor of mortality than osteoporosis in patients, highlighting the need for muscle health assessment.

The prevalence of hyperuricemia in patients with chronic kidney disease (CKD) is high, but the management is suboptimal under traditional treatment. This study was conducted to clarify whether febuxostat achieves better renal survival and patient outcome compared with traditional urate-lowering agents (ULAs). In total, 2,460 adults who had continuously received ULAs for at least three months before enrollment were investigated. Three groups were compared prospectively including non-conversion (n = 2,214), conversion (n = 206), and febuxostat first (n = 40). We evaluated laboratory changes, estimated glomerular filtration rate (eGFR) change, eGFR decline, renal survival, and all-cause mortality. The Cox proportional hazard risk analysis were also used for risk prediction. Multiple prescriptions for ULAs were found in both the non-conversion and conversion groups. However, improved median eGFR was noted in the febuxostat group (p < 0.001), median serum uric acid (SUA) level decreased from 9.45 to 6.7 mg/dL in the febuxostat group (p = 0.010), and median SUA decreased from 8.5 to 6.3 mg/dL in the conversion group (p < 0.001). Decline rate was retarded in the conversion (p = 0.050). Using the Cox proportional model, the multivariate analysis showed conversion group, young age, and relatively good baseline eGFR were associated with better renal outcome [Hazard ratio (HR) = 0.51, 95% confidence interval (CI) = 0.39–0.69]. Febuxostat had a beneficial effect on renal outcome and hyperuricemia in CKD patients. In summary, our results support the use of aggressive treatment with febuxostat in CKD patients.

Objective: To examine the long-term risk of stroke in women who have experienced symptomatic menopausal transition. Methods: In this nationwide, population-based cohort study conducted from January 1, 2000 to December 31, 2013, we identified 22,058 women with no prior history of stroke, who experienced symptomatic menopausal transition at ≥45 years of age. Moreover, 22,058 women without symptomatic menopause were matched by propensity scores and enrolled as a comparison group. The propensity score was calculated by using all characteristic variables of each subject, including demographics (age and monthly income), comorbidities (hypertension, hyperlipidemia, diabetes mellitus, obesity, chronic kidney disease, coronary artery disease, congestive heart failure, chronic obstructive pulmonary disease, dysrhythmia, peripheral artery occlusive disease), Charlson’s comorbidity index score, clinic visit frequency, and long-term medications (antihypertensives, antidiabetic agents, statins, antiplatelets, aspirin, warfarin, and hormone replacement therapy). The primary endpoint was the development of stroke after the onset of symptomatic menopausal transition. The Fine and Gray’s proportional subhazards model was performed to assess the association between symptomatic menopausal transition and subsequent stroke. All subjects were followed up until December 31, 2013. Results: During a mean follow-up of 8.5 years (standard deviation 4.7 years, maximum 14 years), 2,274 (10.31%) women with symptomatic menopausal transition, and 1,184 (5.37%) matched comparison participants developed stroke. The incidence rates were 11.17 per 1,000 person-years in the symptomatic menopausal transition group compared with 8.57 per 1,000 person-years in the comparison group. The risk of developing stroke was significantly higher in women with symptomatic menopausal transition (crude subhazard ratio, 1.31; 95% confidence interval (CI) [1.22–1.41]; P < 0.001). After adjusting for demographics, comorbidities, clinic visit frequency, and long-term medications, the risk of stroke remained statistically significant (adjusted subhazard ratio, 1.30; 95% CI [1.21–1.40]; P < 0.001). Moreover, subgroup analyses revealed no evidence for inconsistent effects for symptomatic menopausal transition on subsequent risk of stroke across all subgroups except age, comorbidities, hypertension, and use of antihypertensives. Women with early menopausal transition (before age 50), without comorbid condition, without hypertension, or without use of antihypertensives are at a higher risk of stroke. The longer duration of symptomatic menopausal transition was associated with higher risk of stroke (P for trend < 0.001). Conclusion: In this large-scale retrospective cohort study, symptomatic menopausal transition was statistically significantly associated with a 30% increased risk of stroke. Further prospective studies are required to confirm our findings.